Naoko Hattori

Title: Naoko Hattori: Innovator in Cancer Therapeutics

Introduction

Naoko Hattori is a prominent inventor based in Tokyo, Japan. She has made significant contributions to the field of cancer therapeutics, particularly through her innovative research and development of novel compounds.

Latest Patents

Hattori holds a patent for a DNMT inhibitor as a solid tumor therapeutic drug. This invention addresses the need for an effective medicine that can serve as a therapeutic or prophylactic drug for various advanced solid tumors. The compound is designed to have high stability against cytidine deaminase, allowing for oral administration and integration into nucleic acid biosynthetic pathways while inhibiting DNA methyltransferases (DNMTs).

Career Highlights

Throughout her career, Naoko Hattori has worked with notable companies, including Ohara Pharmaceutical Co., Ltd. and Toudai Tlo, Ltd. Her work has been instrumental in advancing therapeutic options for patients with high-risk myelodysplastic syndromes and other solid tumors.

Collaborations

Hattori has collaborated with esteemed colleagues such as Sako Magoichi and Toshikazu Ushijima. These partnerships have further enhanced her research and development efforts in the field of cancer therapeutics.

Conclusion

Naoko Hattori's innovative work in developing DNMT inhibitors showcases her commitment to improving cancer treatment options. Her contributions are paving the way for new therapeutic strategies in oncology.